Does Biosilicon deliver? Uni of Pittsburgh to investigate
Friday, 21 May, 2004
Nanotechnology company pSivida's (ASX: PSD) UK subsidiary pSiMedica has signed a collaborative agreement with the University of Pittsburgh to evaluate the use of BioSilicon as a delivery platform for the university's proprietary DNA vaccine technology.
The company will work with the laboratory of Prof Ted Ross, which has experience in developing DNA vaccines for viral diseases to build on prior work performed by pSiMedica on the loading into and release of DNA from BioSilicon matrices to effectively produce the immunogen carried by the DNA sequence.
pSivida managing director Gavin Rezos said the agreement demonstrated the increasing profile of pSivida and pSiMedica in the US.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
